Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR3906] to ABI2
- Suitable for: ICC/IF, IHC-P
- Reacts with: Mouse, Rat, Human
Product nameAnti-ABI2 antibody [EPR3906]
See all ABI2 primary antibodies
DescriptionRabbit monoclonal [EPR3906] to ABI2
Tested applicationsSuitable for: ICC/IF, IHC-Pmore details
Unsuitable for: Flow Cyt
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human ABI2 aa 150-250. The exact sequence is proprietary.
- HeLa, Jurkat, K562, SH-SY5Y and HepG2 cell lysates. Paraffin-embedded Human brain tissue.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab108340 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||1/500 - 1/1000.|
|IHC-P||1/250 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionMay act in regulation of cell growth and transformation by interacting with nonreceptor tyrosine kinases ABL1 and/or ABL2. Part of the WAVE complex that regulates lamellipodia formation. The WAVE complex regulates actin filament reorganization via its interaction with the Arp2/3 complex. Regulates ABL1/c-Abl-mediated phosphorylation of MENA.
Sequence similaritiesBelongs to the ABI family.
Contains 1 SH3 domain.
Contains 1 t-SNARE coiled-coil homology domain.
modificationsIs a substrate for ABL1.
Cellular localizationCytoplasm and Cell projection > lamellipodium. Cell projection > filopodium. Cytoplasm > cytoskeleton. Isoform 1 but not isoform 3 is localized to protruding lamellipodia and filopodia tips.
- Information by UniProt
- Abelson interactor 2 antibody
- ABI 2 antibody
- Abi-2 antibody
ab108340 has been referenced in 1 publication.
- Crawford LJ et al. Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models. Oncogenesis 3:e90 (2014). WB ; Human . PubMed: 24590311